Ryu Kanzaki

Dr. Ryu Kanzaki

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in European Urology
Verified
Journal Article
Closed access
MAMohammad Abufaraj
Mohammad Abufaraj
GDGuido Dalbagni
Guido Dalbagni
SDSiamak Daneshmand
Siamak Daneshmand
SHSimon Horenblas
Simon Horenblas
AKAshish M. Kamat
Ashish M. Kamat
SSShahrokh F. Shariat
Shahrokh F. Shariat

1 March 2011 in Lung Cancer
Verified
Journal Article
Closed access
RKRyu Kanzaki
Ryu Kanzaki
MHMasahiko Higashiyama
Masahiko Higashiyama
AFAyako Fujiwara
Ayako Fujiwara
TTToshiteru Tokunaga
Toshiteru Tokunaga
JMJun Maeda
Jun Maeda
KKKen Kodama
Ken Kodama

1 February 2011 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
RKRyu Kanzaki
Ryu Kanzaki
MHMasahiko Higashiyama
Masahiko Higashiyama
AFAyako Fujiwara
Ayako Fujiwara
TTToshiteru Tokunaga
Toshiteru Tokunaga
JMJun Maeda
Jun Maeda
KKKen Kodama
Ken Kodama
Despite the report of new treatment options, surgery remains the best treatment for pulmonary metastases from renal cell carcinoma (RCC). Repeat resection is also an effective means for recurrent pulmonary metastases. The aim of the present study was to define the prognostic factors for survival after pulmonary metastasectomy from RCC based on a 25-year single-centre experience. Between 1973 and 2008, 59 thoracotomies on 48 patients (38 men, 10 women) were performed in our hospital. Repeat resections were performed in eight patients. The clinicopathological and surgical data of these patients obtained from the medical records were analysed. The time interval between lung resection and death, or latest follow-up, ranged from 3 to 177 months (median 39 months). Survival analysis was conducted by the Kaplan-Meier method and log-rank test. Multivariate analysis was performed using the Cox multivariate proportional hazard model. The cumulative 3-, 5- and 10-year survival rates were 60%, 47% and 18%, respectively. Multivariate analysis identified disease-free interval (DFI) (≥ 2 years) and complete resection as significant prognostic factors for survival. Among eight patients, who underwent repeat resection, two remain alive with no evidence of disease. These two patients had long DFI and long DFI-2 (time from first pulmonary metastasectomy to diagnosis of recurrent pulmonary metastasis). The results showed that (1) surgical resection of pulmonary metastasis from RCC has a favourable outcome in selected patients, (2) DFI and completeness of resection are prognostic markers for survival after pulmonary metastasectomy and (3) repeat lung resection for metastatic RCC is a safe procedure that provides satisfactory patient outcomes.

5 July 2021 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
SWShan Wang
Shan Wang
EEEmelie Englund
Emelie Englund
PKPontus Kjellman
Pontus Kjellman
ZLZhen Li
Zhen Li
JAJohannes Kumra Ahnlide
Johannes Kumra Ahnlide
CMChris D. Madsen
Chris D. Madsen

1 October 2011 in The American Journal of Surgery
Verified
Journal Article
Closed access
RKRyu Kanzaki
Ryu Kanzaki
MHMasahiko Higashiyama
Masahiko Higashiyama
KOKazuyuki Oda
Kazuyuki Oda
AFAyako Fujiwara
Ayako Fujiwara
TTToshiteru Tokunaga
Toshiteru Tokunaga
KKKen Kodama
Ken Kodama

1 June 2010 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
RKRyu Kanzaki
Ryu Kanzaki
MHMasahiko Higashiyama
Masahiko Higashiyama
JMJun Maeda
Jun Maeda
JOJiro Okami
Jiro Okami
THTakuya Hosoki
Takuya Hosoki
KKKen Kodama
Ken Kodama
Objectives: F18-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT), which allows differentiation between malignant and